Notice2021-14681
Prospective Grant of an Exclusive Patent License: High ASS1 Expressing Tumors Embody a Purine Rich Genomic Signature and Sensitivity to Purine Depletion
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 12, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute (NCI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Yeda Research & Development Co, Ltd ("YEDA"), the technology transfer company of the Weizmann Institute of Science, a non-profit research institution located in Rehovot, Israel for NCI's rights to the patent applications listed in the Supplementary Information section of this notice.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 130 (Monday, July 12, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 130 (Monday, July 12, 2021)]
[Notices]
[Page 36567]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-14681]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: High ASS1
Expressing Tumors Embody a Purine Rich Genomic Signature and
Sensitivity to Purine Depletion
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute (NCI), an institute of the
National Institutes of Health, Department of Health and Human Services,
is contemplating the grant of an exclusive, sublicensable patent
license to Yeda Research & Development Co, Ltd (``YEDA''), the
technology transfer company of the Weizmann Institute of Science, a
non-profit research institution located in Rehovot, Israel for NCI's
rights to the patent applications listed in the Supplementary
Information section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before July 27, 2021 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Kevin W. Chang, Ph.D., Senior Licensing and
Patenting Manager at Telephone: (240)-276-6910 or at Email:
<a href="/cdn-cgi/l/email-protection#690a0108070e020c290408000547070001470e061f"><span class="__cf_email__" data-cfemail="492a2128272e222c092428202567272021672e263f">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
The following and all continuing U.S. and foreign patents/patent
applications thereof are the intellectual properties to be licensed
under the prospective agreement to YEDA: PCT Patent Application PCT/
IL2020/050708, filed June 24, 2020 and entitled ``High ASS1 Expressing
Tumors Embody A Purine Rich Genomic Signature And Sensitivity To Purine
Depletion'' [HHS Reference No. E-210-2020-0-PCT-01].
The patent rights in these inventions have been assigned to the
Government of the United States of America and YEDA. The prospective
license will be for the purpose of consolidating the patent rights to
YEDA, one of the co-owners of said rights, for commercial development
and marketing. Consolidation of these co-owned rights is intended to
expedite development of the invention, consistent with the goals of the
Bayh-Dole Act codified as 35 U.S.C. 200-212.
The prospective patent license will be worldwide, exclusive, and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
YEDA will be subject to the provisions of 37 CFR parts 401 and 404.
This technology discloses methods of treating a high
argininosuccinate synthase (ASS1) expressing solid tumor with a
combination of a purine synthase inhibitor or an agent that increases
the pyrimidine to purine ratio in a cell, and an immune-modulating
drug, such as a checkpoint inhibitor.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will include terms for the
sharing of royalty income with NCI from commercial sublicenses of the
patent rights. The prospective exclusive license may be granted unless
within fifteen (15) days from the date of this published notice, the
National Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: July 6, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2021-14681 Filed 7-9-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 12, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.